What is Aptimmune?
Aptimmune Biologics is at the forefront of developing advanced mucosal vaccines designed to combat critical swine diseases, including Porcine Reproductive and Respiratory Syndrome virus (PRRSv) and Swine Influenza A virus. Leveraging its proprietary Barricade platform technology, the company offers targeted solutions to stakeholders across various geographical regions. Aptimmune is also actively engaged in research and development for vaccines against the African Swine Fever virus, aiming to provide comprehensive disease protection and enhance animal health within the swine industry.
How much funding has Aptimmune raised?
Aptimmune has raised a total of $10.6M across 3 funding rounds:
Private Equity
$2.4M
Series A
$2.2M
Series B
$6M
Private Equity (2015): $2.4M, investors not publicly disclosed
Series A (2017): $2.2M led by Fox Ventures, LLC and Arsenal Capital Management
Series B (2018): $6M supported by St Louis Arch Angels, Cultivation Capital, Missouri Technology, Yield Lab, and Arsenal Capital Management
Key Investors in Aptimmune
Arsenal Capital Management
Arsenal Capital Partners is a leading private equity firm specialized in investments in middle-market industrial growth and healthcare companies. Since its inception in 2000, the firm has distinguished itself through a "build-for-tomorrow" philosophy, focusing on high-growth, technology-, and innovation-rich businesses that are strategically important to their respective markets. Arsenals investment strategy is deeply rooted in sector expertise; the firm employs a team of nearly 100 professionals that includes seasoned industry executives, scientists, and technical experts. This allows the firm to partner effectively with management teams to execute multi-faceted growth strategies, often involving complex buy-and-build models.
Cultivation Capital
Cultivation Capital is a venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences, software, agriculture, and geospatial technology. The firm provides capital resources and a vast network of partners to help startups navigate the challenges of hyper growth from Series Seed through Series B. With a focus on the Midwest, Cultivation Capital aims to support companies that have achieved measurable milestones and demonstrate potential for success. Their portfolio includes a diverse range of innovative companies that are poised to make significant impacts in their respective fields.
St Louis Arch Angels
The St. Louis Arch Angels is a network of accredited investors dedicated to funding early-stage businesses in the St. Louis region. Since its inception in 2005, the organization has invested over $100 million in more than 100 startups, aiming to enhance the local business climate while providing financial returns. Its members include experienced business leaders, engineers, physicians, and scientists who are committed to fostering economic growth in the area. The organization supports innovative ventures such as IDEATE Medical, CoverCress, and Aptimmune Biologics, which address various industry challenges.
What's next for Aptimmune?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Aptimmune. This capital infusion is expected to fuel further research and development, potentially expanding the company's vaccine pipeline and enhancing its Barricade platform's capabilities. Aptimmune is strategically positioned to address significant unmet needs in swine disease prevention, and this latest round of financing will likely support scaling its operations, expanding market reach, and potentially pursuing regulatory approvals for its innovative vaccine candidates. The company's focus on high-impact diseases like PRRSv and African Swine Fever indicates a clear trajectory towards becoming a leader in animal health.
See full Aptimmune company page
